ARTICLE | Clinical News
Lyxumia lixisenatide regulatory update
October 5, 2015 7:00 AM UTC
FDA accepted for review an NDA from Sanofi for lixisenatide to treat Type II diabetes. Sanofi submitted the NDA in late July (see BioCentury, Sept. 16, 2013). The glucagon-like peptide-1 receptor ( G...